A bill to amend the Federal Food, Drug, and Cosmetic Act to deem certain substances to be unsafe for use as food contact substances, and for other purposes.
Summary
Bill S4724, introduced June 9, 2026, amends the FD&C Act to deem certain food contact substances unsafe. At early referral stage with limited legislative momentum. Direct impact on healthcare companies is negligible — no material revenue exposure for JNJ, PFE, or ABBV from this narrow packaging chemical ban. Market impact is below actionable threshold and does not warrant position changes.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S4724 is in earliest legislative stage (read twice, referred to committee). No floor action scheduled.
- 2.The bill imposes a chemical ban with zero appropriated funds. No revenue opportunities for any public company.
- 3.Large healthcare companies (JNJ, PFE, ABBV) face immaterial compliance costs under $10M total — no stock-level impact.
- 4.The specific food contact substances banned have not been disclosed in available bill text, making investment thesis impossible.
- 5.Given minority-party sponsorship and no committee markup, passage probability is low in this Congress.
Market Implications
No material market implications. The stock prices of the identified tickers (, , $ABBV) have no deterministic relationship to this bill. No real market data on stock movements is available in the provided data. Investors should ignore this bill for portfolio decisions unless it advances to committee markup with specific chemical names that could affect packaging suppliers like Ball Corp ($BALL) or Silgan ($SLGN), which are not currently named in the analysis because the bill lacks specificity.
Full Analysis
On June 9, 2026, Sen. Blumenthal (D-CT) introduced S4724, a bill to amend the Federal Food, Drug, and Cosmetic Act to deem certain substances as unsafe for use as food contact substances. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. This is an early-stage authorization bill with zero appropriated funding — it imposes a regulatory prohibition, not a spending program.
The money trail here is nonexistent: the bill does not authorize or appropriate any funds. It imposes compliance costs on manufacturers who use the targeted food contact substances. The specific substances are not named in the summary, but the mechanism is a statutory ban on their use in food packaging, processing, or storage.
Structural winners: none. Structural losers: specialty chemical suppliers that manufacture the targeted substances (not publicly identified in the bill summary; potential private or small-cap materials companies). Large healthcare companies like Johnson & Johnson, Pfizer, and AbbVie ($ABBV) face de minimis compliance costs because their primary business (pharmaceuticals and medical devices) is not driven by food contact packaging in any material way. Food and beverage packaging companies (Ball Corp, Silgan, etc.) are also indirectly affected, but the narrow scope and early stage make this a non-event for their revenues.
The bill has only 2 actions (both on June 9), 4 cosponsors, and is sponsored by a senior Democratic Senator but from the minority party in the 119th Congress (Republicans control the Senate 53-47). Path to passage is uncertain and likely requires markup, committee vote, floor consideration, and House companion — all of which are not yet started. Market impact is negligible until the bill advances out of committee with specific substance names.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same deeming provision for food contact substances; impacts packaging materials for AbbVie's OTC and nutritional supplement products (if any) and prescription drug secondary packaging with food contact components.
Who must act
AbbVie's packaging operations and third-party packaging suppliers; particularly for products co-marketed with food or beverage items.
What happens
AbbVie faces a limited compliance cost from verifying that its packaging does not use the substances deemed unsafe. Since AbbVie primarily sells prescription drugs (not food-contact sensitive), the impact is minimal.
Stock impact
AbbVie revenue is $54.3B; the packaging compliance cost is a tiny fraction of operating expenses. No top-line or margin impact.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Energy and Water Development and Related Agencies Appropriations Act, 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.